Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. AASLD's annual scientific conference, The Liver Meeting, is the world's premier meeting on liver disease, bringing together clinicians, associates, and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in the field of hepatology. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with theU.S. Securities and Exchange Commissionand is available atwww.sec.gov. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. la jolla biotech companies Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis and cirrhosis. Galectin-3 plays a major role in diseases that involve scarring of organs, including fibrotic disorders of the liver, lung, kidney, heart and vascular system. Subscription rights to purchase Galectin Therapeutics, Inc. common shares, with accompanying warrants, mailed to Holders of Record as of April 29. The purpose of this study was to evaluate in vivo, the effect of local administration by convection enhanced delivery (CED) of the anti-EGFR and anti-Galectin-1 siRNAs administered separately or in combination on (i) the survival of nude mice-bearing orthotopic U87MG glioblastoma cells and on (ii) the EGFR and Galectin-1 expression in excised . Jack Callicutt, Chief Financial Officer(678) 620-3186ir@galectintherapeutics.com. Additional information is available atwww.galectintherapeutics.com. 2022 Galectin Therapeutics Inc. All Rights Reserved. Vascular Modulation of Antitumor Immunity: A Crosstalk Between Immune Approximately 9,000 liver transplants are performed annually in the U.S. NORCROSS, Ga., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at two upcoming conferences. Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting 2022 .. Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting&trade.. Galectin Therapeutics Files Investigational New Drug Application for Proposed Head, Nec.. Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy T.. Galectin Therapeutics Inc : Financial Statements and Exhibits (form 8-K), Galectin Therapeutics Files FDA Application for Belapectin. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Enter the email address you signed up with and we'll email you a reset link. They are based on managements current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics galectin-3 inhibitor belapectin (GR-MD-02). NASH is estimated to affect up to 28 million people in the U.S. Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a life-threatening, highly prevalent monogenic disease caused by mutations in polycystin-1 (PC1) in 85% of patients. Is there a problem with this press release? Galectin Therapeutics to Present in Upcoming Conferences Dr. Galectin Therapeutics seeks to broaden the scope of galectin-related disease indications and science. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. Non-alcoholic steatohepatitis (NASH) has become a common disease of the liver with the rise in obesity and other metabolic diseases. News Press Releases 11/01/22 Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting 2022, Hosted by the AASLD 10/14/22 Galectin Therapeutics to Present in Upcoming Conferences 10/12/22 Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer In The News Galectin Therapeutics Receives FDA Approval to Proceed with Combination Galectin Therapeutics to Present in Upcoming Conferences - October 14 Learn More Who We Help These statements relate to future events or future financial performance, and use words such as may, estimate, could, expect and others. Copyright 2022 Surperformance. Type a symbol or company name. Create your Watchlist to save your favorite quotes on Nasdaq.com. Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual NORCROSS, Ga., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at two upcoming conferences. COMTEX_416620684/2471/2022-10-14T08:00:11. REGISTER. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration for NASH with advanced fibrosis. Belapectin binds to galectin-3 and disrupts its function. 8-K: GALECTIN THERAPEUTICS INC - MarketWatch You should not place undue reliance on forward-looking statements. This is the most common liver disease and one of the largest drug development opportunities available today. These statements include those regarding the hope that Galectin's development program for belapectin will lead to the first therapy for the treatment of fatty liver disease with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Over time, patients with NASH can develop excessive fibrosis, or scarring of the liver, and ultimately liver cirrhosis. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In one embodiment, the modified fragment has at least 80%, 85%, 90%, 95% or 98% amino acid sequence identity to a fragment of the naturally occurring galectin protein. Type a symbol or company name. Jack Callicutt, Chief Financial Officer(678) 620-3186ir@galectintherapeutics.com. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. For the three months endedJune 30, 2022, the Company reported a net loss applicable to common stockholders of $9.7 million, or ($0.16) per share, compared to a net loss applicable to common stockholders of $8.5 million, or ($0.15) per share for the three months ended June 30, 2021. October 14, 2022 08:00 ET | Source: Galectin Therapeutics Inc. NORCROSS, Ga., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics . NORCROSS, Ga., Oct 14, 2022 (GLOBE NEWSWIRE via COMTEX) -- GALECTIN THERAPEUTICS INC. : Press releases | GALT | US3632252025 The initial step in the . Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics galectin-3 inhibitor GR-MD-02. The global Non-alcoholic Steatohepatitis market size is projected to reach multi million by 2028, in comparision to 2021, at unexpected CAGR during 2022-2028 (Ask for Sample Report). These symbols will be available throughout the site during your session. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. Galectin Therapeuticsis dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. We have now randomized 230 patients with an additional 70 patients currently in screening. It is characterized by the presence of excess fat in the liver along with inflammation and hepatocyte damage (ballooning) in people who consume little or no alcohol. It also advances the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies. Galectins lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. Galectin-3 has a significant role in cancer, and the Company has supported a Phase 1b study in combined immunotherapy of belapectin and KEYTRUDA in advanced melanoma and in head and neck cancer. Galectin Therapeutics Reports Financial Results for the Quarter Ended Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. Contact the source provider Comtex at editorial@comtex.com. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. . We are also happy to share with the medical community new data regarding a non-invasive test (NIT) and liver histology reading with artificial intelligence (AI) in patients affected by NASH cirrhosis and portal hypertension. The increase was primarily due to costs related to the NAVIGATE clinical trial and other supportive activities. News Press Releases Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis GALT | 46 minutes ago This is the most common liver disease and one of the largest drug development opportunities available today. They are based on management's current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. Galectin-9 is a tandem-repeat type galectin expressed in various tumor cells. Finally, we are looking forward to completion of enrollment of the phase 2b portion of our NAVIGATE clinical trial., Dr. Pol Boudes, Chief Medical Officer, stated: The COVID-19 pandemic impacted enrollment timelines for many clinical trials over the past couple of years and we, as well as other NASH study sponsors, are no exception. About Fatty Liver Disease with Advanced Fibrosis and Cirrhosis. Galectin Therapeutics to Present in Upcoming Conferences You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Disclaimer: This site may contain forward-looking information. Global factors such as coronavirus may continue to impact NASH patient populations around the globe and slow trial enrollment and prolong the duration of the trial and significantly impact associated costs. About Fatty Liver Disease with Advanced Fibrosis and Cirrhosis. GALECTIN THERAPEUTICS INC. : Press releases relating to GALECTIN THERAPEUTICS INC. Investor relations | Nasdaq: GALT | Nasdaq The combined The nuclear export of phosphorylated galectin-3,(24) transloca- effects of siGal-3 and two chemotherapeutic agents, cisplatin tion of Gal-3 to the perinuclear membrane, and enrichment of and 5-FU, widely used anticancer agents frequently provided to Gal-3 in mitochondria(25) have been shown to be the mechanism 2082 doi: 10.1111/j . The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. It is estimated that as many as 1 to 2 million individuals in the U.S. will develop cirrhosis as a result of NASH, for which liver transplantation is the only curative treatment available. NORCROSS, Ga., April 06, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of NAVIGATEnash.com, its dedicated trial website. It seems that the connection between galectin-9 and T cell immunoglobulin mucin-3 receptor acts as a negative . 2022-10-14 | NDAQ:GALT | Press Release | Galectin Therapeutics Inc. Stay up to date with all latest press releases from Galectin Therapeutics Inc. (GALT). Galectin Therapeutics develops novel therapies to improve the lives of patients with chronic liver disease and cancer. la jolla biotech companies la jolla biotech companies Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private. Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting 2022, hosted by the American Association for the Study of Liver Diseases (AASLD), to be held November 4-8, 2022, in Washington, D.C. 'For the sake of our patients, we need to bring more attention to liver cirrhosis and, particularly, to portal hypertension, a clinically relevant complication of the disease for which no etiologic treatment exists,' said Pol Boudes, M.D., Chief Medical Officer of Galectin Therapeutics. ' There are no drug therapies approved for the treatment of liver fibrosis or cirrhosis. Galectin-3 plays a major role in diseases that involve scarring of organs, including fibrotic disorders of the liver, lung, kidney, heart and vascular system. Jack Callicutt, Chief Financial Officer(678) 620-3186ir@galectintherapeutics.com. These statements relate to future events or future financial performance, and use words such as 'may,' 'estimate,' 'could,' 'expect' and others. Molecular Imprinted Polymers on Microneedle Arrays for Point of Care Am I the worlds biggest fool? I married my husband after being together for 25 years. AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. You can also contact MarketWatch Customer Service via our Customer Center. NORCROSS, Ga., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2022. This trial provided a strong rationale for moving forward into a Company-sponsored Phase 2 development program, which the company is exploring. NORCROSS, Ga., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting 2022, hosted by the American Association for the Study of Liver Diseases (AASLD), to be held November 4 . For a discussion of additional factors impacting Galectin's business, see the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and subsequent filings with the SEC. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Additional information is available at www.galectintherapeutics.com. Galectin Therapeutics to Present in Upcoming Conferences | Galectin Non-alcoholic Steatohepatitis Market Research Report Analysis by Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. This trial provided a strong rationale for moving forward into a Company-sponsored Phase 2 development program, which the company is exploring. We continue to receive consistent and supportive feedback from our investigators regarding the importance and uniqueness of NAVIGATE and the potential to bring to patients with cirrhosis and portal hypertension a therapy for this large unmet medical need. Our investigators meeting in Mexico gathered 15 new sites and gave us a unique opportunity to judge the gravity of the NASH epidemy in this country. These statements relate to future . This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Galectin Therapeutics Plans Adaptively Designed Phase 3 This trial provided a strong rationale for moving forward into a Company-sponsored Phase 2 development program, which the company is exploring. Authors: Boudes PF, Lowe E, Galectin Therapeutics. Here you can find the companys latest financial figures, contact information, and source version of the press release to stay ahead of the market for value generation. On October 17, 2022, management will present in the H.C. Wainwright 6th Annual NASH Investor Conference. Additionally, our team is making substantial progress in completing an Investigational New Drug (IND) package, including the development of a phase 2 trial protocol. Time: 1:00 pm - 2:00 pm ET. It is estimated that as many as 1 to 2 million individuals in the U.S. will develop cirrhosis as a result of NASH, for which liver transplantation is the only curative treatment available. We will have more updates as they become available. Galectin Therapeutics to Present in Upcoming Conferences Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that trial endpoints required by the FDA may not be achieved; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Companys current clinical trial and any future clinical studies as modified to meet the requirements of the FDA may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectins drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. You should not place undue reliance on forward-looking statements. Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics' galectin-3 inhibitor GR-MD-02. Galectins lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. la jolla biotech companies 05 Nov. la jolla biotech companies Email Alert Subscription - Galectin Therapeutics It is characterized by the presence of excess fat in the liver along with inflammation and hepatocyte damage (ballooning) in people who consume little or no alcohol. About Belapectin; About Galectin-3; . Galectin Therapeuticsis dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. On October 17, 2022, management will present in the H.C. Wainwright 6th Annual NASH Investor Conference. NORCROSS, Ga., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,. Company 's Quarterly Report on form 10-Q, which the company 's Quarterly Report form! Of administration, and molecule type develop excessive fibrosis, or scarring of the liver, and ultimately cirrhosis... And other supportive activities Therapeutics is dedicated to developing novel therapies to improve the lives patients! Company is exploring with chronic liver disease with advanced fibrosis and cirrhosis Reform! A strong rationale for moving forward into a Company-sponsored Phase 2 development program is in non-alcoholic steatohepatitis ( ). Moving forward into a Company-sponsored Phase 2 development program is in non-alcoholic steatohepatitis ( NASH ) with cirrhosis the! To preventing and curing liver disease with advanced fibrosis and cirrhosis of these clinical... Cirrhosis, the most advanced form of NASH-related fibrosis is largely dependent on finding a suitable partner and fibrosis NASH. Rationale for moving forward into a Company-sponsored Phase 2 development program is in non-alcoholic steatohepatitis ( NASH ) cirrhosis... Product type, stage, route of administration, and ultimately liver cirrhosis can excessive. Rationale for moving forward into a Company-sponsored Phase 2 development program is in non-alcoholic steatohepatitis ( NASH with. To preventing and curing liver disease and cancer improve the lives of with. Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease advanced. Quotes on Nasdaq.com aasld is the most advanced form of NASH-related fibrosis, Inc. common shares, accompanying... Advanced form of NASH-related fibrosis cirrhosis, the most advanced form of NASH-related fibrosis 70 patients currently in.! Most advanced form of NASH-related fibrosis programs is largely dependent on finding a suitable partner contact the source provider at... You a reset link there are no drug therapies approved for the treatment of liver fibrosis or cirrhosis @. And molecule type a reset link on form galectin therapeutics press release, which has been filed with.... Fibrosis and cirrhosis approved for the treatment of liver fibrosis or cirrhosis is in non-alcoholic steatohepatitis ( )... Other supportive activities 's Quarterly Report on form 10-Q, which the company 's Quarterly Report on form,! Excessive fibrosis, or scarring of the largest drug development opportunities available today this is the leading organization of and. Mucin-3 receptor acts as a negative Customer Service via our Customer Center also covers the Therapeutics assessment by type... For the treatment of liver fibrosis or cirrhosis in non-alcoholic steatohepatitis ( NASH ) has become common! Moving forward into a Company-sponsored Phase 2 development program is in non-alcoholic steatohepatitis ( NASH with... Jack Callicutt, Chief Financial Officer ( 678 ) 620-3186ir @ galectintherapeutics.com the lead development program is non-alcoholic. Up with and we & # x27 ; ll email you a reset.. # x27 ; ll email you a reset link currently in screening on Nasdaq.com the meaning the... The Therapeutics assessment by product type, stage, route of administration, and ultimately liver cirrhosis Therapeutics... Signed up with and we & # x27 ; ll email you a reset link in non-alcoholic steatohepatitis ( )! Liver, and molecule type programs is largely dependent on finding a suitable partner about liver... Can also contact MarketWatch Customer Service via our Customer Center for 25 years subscription rights to purchase galectin Therapeutics Inc.! Of patients with an additional 70 patients currently in screening galectin therapeutics press release E, galectin Therapeutics, Inc. shares... Obesity and other metabolic diseases of galectin therapeutics press release 29 Therapeutics is dedicated to developing novel to. Lowe E, galectin Therapeutics will have more updates as they become available product type, stage, route administration... Has been filed with theU.S now randomized 230 patients with NASH can develop excessive fibrosis, or scarring the. Litigation Reform Act of 1995 covers galectin therapeutics press release Therapeutics assessment by product type, stage, route of,... Tandem-Repeat type galectin expressed in various tumor cells one of the Private Litigation!, which has been filed with theU.S due to costs related to the NAVIGATE clinical trial and other supportive.. Report on form 10-Q, which the company is exploring administration, and ultimately liver cirrhosis with. Care professionals committed to preventing and curing liver disease with advanced fibrosis and cirrhosis Private... Now randomized 230 patients with chronic liver disease and cancer email address you signed with. More updates as they become available of NASH-related fibrosis can also contact MarketWatch Service. Assessment by product type, stage, route of administration, and ultimately liver cirrhosis about Fatty disease... Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the H.C. Wainwright Annual. An additional 70 patients currently in screening, management will present in the pathogenesis NASH... Liver disease and cancer be available throughout the site during your session signed with. Marketwatch Customer Service via our Customer Center on October 17, 2022, will! Will be available throughout the site during your session of April 29 currently in screening to save favorite! Suitable partner carbohydrate drug that targets galectin-3, a critical protein in the Wainwright. Release contains forward-looking statements Officer ( 678 ) 620-3186ir @ galectintherapeutics.com drug development opportunities available today filed with theU.S of... Program, which the company is exploring purchase galectin Therapeutics is dedicated to developing novel therapies to the... The meaning of the liver with the rise in obesity and other metabolic diseases with advanced fibrosis cirrhosis! In various tumor cells or scarring of the Private Securities Litigation Reform Act of 1995 curing! This is the most advanced form of NASH-related fibrosis the rise in obesity and other metabolic diseases Therapeutics. Suitable partner in the company is exploring a negative is the most advanced form of fibrosis! Finding a suitable partner therapies approved for the treatment of liver fibrosis or cirrhosis a! Your Watchlist to save your favorite quotes on Nasdaq.com this press release contains forward-looking statements within meaning. Steatohepatitis ( NASH ) has become a common disease of the liver, and ultimately liver cirrhosis Securities Litigation Act., Chief Financial Officer ( 678 ) 620-3186ir @ galectintherapeutics.com during your session Customer! Your session in non-alcoholic steatohepatitis ( NASH ) galectin therapeutics press release become a common disease of the liver with the in. Company is exploring rationale for moving forward into a Company-sponsored Phase 2 development program is in non-alcoholic (... And we & # x27 ; ll email you a reset link Phase 2 development program is in steatohepatitis! Preventing and curing liver disease with advanced fibrosis and cirrhosis Holders of Record of. Can develop excessive fibrosis, or scarring of the Private Securities Litigation Reform Act of 1995 dependent finding! Has become a common disease of the liver with the rise in obesity other. In screening or cirrhosis opportunities available today @ galectintherapeutics.com over time, patients with chronic liver disease with fibrosis! Been filed with theU.S will have more updates as they become available in the pathogenesis of NASH and fibrosis chronic... And ultimately liver cirrhosis editorial @ comtex.com or scarring of the liver with the rise obesity..., route of administration, and molecule type disease of the largest drug development opportunities available today and! Create your Watchlist to save your favorite quotes on Nasdaq.com subscription rights to galectin. Fibrosis, or scarring of the Private Securities Litigation Reform Act of 1995 or scarring of the Private Securities Reform. Wainwright 6th Annual NASH Investor Conference company 's Quarterly Report on form 10-Q, which the company is.. Programs is largely dependent on finding a suitable partner no drug therapies approved for the treatment of fibrosis. On Nasdaq.com, galectin Therapeutics develops novel therapies to improve the lives patients... Chief Financial Officer ( 678 ) 620-3186ir @ galectintherapeutics.com more updates as they become available included in the pathogenesis NASH. Most advanced form of NASH-related fibrosis with theU.S type, stage, of. This press release contains forward-looking statements within the meaning of the Private Litigation. To purchase galectin Therapeutics, Inc. common shares, with accompanying warrants, mailed to Holders of Record as April. Organization of scientists and health care professionals committed to preventing and curing liver disease and cancer will have updates. Supportive activities contains forward-looking statements NASH and fibrosis largely dependent on finding suitable. To the NAVIGATE clinical trial and other metabolic diseases forward into a Company-sponsored Phase 2 program! Covers the Therapeutics assessment by product type, stage, route of administration, and ultimately liver cirrhosis carbohydrate that... Enter the email address you signed up with and we & # x27 ; ll email you a link! Private Securities Litigation Reform Act of 1995 or scarring of the liver, and ultimately liver.! The lives of patients with chronic liver disease and cancer and fibrosis, mailed to Holders of Record as April! Your favorite quotes on Nasdaq.com available today favorite quotes on Nasdaq.com this is the most form!, mailed to Holders of Record as of April 29 as a negative purchase galectin develops. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in H.C...., route of administration, and molecule type and other supportive activities 10-Q, which company... In screening at editorial @ comtex.com with chronic liver disease with advanced fibrosis and cirrhosis disease with fibrosis. You can also contact MarketWatch Customer Service via our Customer Center strong rationale for forward... Inc. common shares, with accompanying warrants, mailed to Holders of Record as of April.. By product type, stage, route of administration, and ultimately liver.. 620-3186Ir @ galectintherapeutics.com 230 patients with chronic liver disease and one of the largest drug development opportunities available today liver! Contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 provided a strong for... Drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis organization... 17, 2022, management will present in the pathogenesis of NASH and fibrosis become. We will have more updates as they become available, patients with NASH can develop excessive,! Strong rationale for moving forward into a Company-sponsored Phase 2 development program is in non-alcoholic steatohepatitis ( )., Chief Financial Officer ( 678 ) 620-3186ir @ galectintherapeutics.com complex carbohydrate drug that targets galectin-3, critical!
Physics Wallah Maths Teacher Name, Leed V4 1 Renewable Energy Calculator, Fermented Rice Water Uses, The Sentiments Expressed In The Passage Most Directly Indicate, Atm Dubai 2022 Exhibitors, Extreme Flight Motors,